These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 19996339

  • 1. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group.
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [Abstract] [Full Text] [Related]

  • 2. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, Kimpen JL, van der Ent CK.
    Thorax; 2010 Oct; 65(10):915-20. PubMed ID: 20729233
    [Abstract] [Full Text] [Related]

  • 3. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR, Pressler T, Høiby N.
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [Abstract] [Full Text] [Related]

  • 4. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K.
    J Cyst Fibros; 2013 Jan; 12(1):29-34. PubMed ID: 22762867
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.
    N Engl J Med; 1999 Jan 07; 340(1):23-30. PubMed ID: 9878641
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Delaisi B, Kho P, Kovarik JM.
    J Cyst Fibros; 2009 Sep 07; 8(5):332-7. PubMed ID: 19651542
    [Abstract] [Full Text] [Related]

  • 9. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F, Brockhaus F, Angyalosi G.
    J Cyst Fibros; 2009 Dec 07; 8(6):361-9. PubMed ID: 19747887
    [Abstract] [Full Text] [Related]

  • 10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.
    Pediatr Pulmonol; 2007 Apr 07; 42(4):307-13. PubMed ID: 17352404
    [Abstract] [Full Text] [Related]

  • 11. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M, Müller I, Reinhardt D.
    Eur J Med Res; 2002 Feb 21; 7(2):79-80. PubMed ID: 11891148
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.
    Clin Microbiol Infect; 2005 Sep 21; 11(9):690-703. PubMed ID: 16104983
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M, Poli G, Acerbi D, Santoro D, Cicirello H, Annoni O, Ružička J.
    Pulm Pharmacol Ther; 2013 Apr 21; 26(2):249-55. PubMed ID: 23232039
    [Abstract] [Full Text] [Related]

  • 19. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct 21; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 20. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC, Brown R, Sacco P, Zhang J.
    J Med Econ; 2010 Oct 21; 13(3):492-9. PubMed ID: 20670159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.